Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another
Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T RICHMOND, Calif.
Sign-up for Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV-Infected Subjects Treated with SB-728-T investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage
biopharmaceutical company developing T cell-enabled vaccines and
immunotherapies, today presented data from a Phase 1/2a study of
GEN-003, the Company’s investigational immunotherapy against HSV-2,
demonstrating that the immunotherapy elicited T cell, IgG and
neutralizing antibody responses that remained significantly above
baseline for 12 months after treatment.
Sign-up for QLT Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT investment picks
Sign-up for Intra-Cellular Therapies to Present Results From Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia at the American Neurological Association 139th Annual Meeting investment picks
Leading business management thinker Peter Drucker is author of Managing for Results, which is now available in Elsevier's Legacy Collection.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.